Mironid Doses First Patients in Phase 1 Trial of LoAc® Therapy for ADPKD

Phase 1 study is evaluating the safety, tolerability and pharmacokinetics of Mironid’s lead LoAc® small molecule in healthy volunteers Dosing ...

October 02, 2026 | Friday | News
Ensera Launches Alliance Network to Streamline Drug-Device Combination Product Commercialisation

Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, bringing together l...

October 02, 2026 | Friday | News
Rakovina Therapeutics and Celvion Partner to Advance AI-Driven Precision Cancer Therapies

Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered d...

October 02, 2026 | Friday | News
Roche Launches Newborn Screening Test for SMA, SCID and Sickle Cell Disease

This test expands Roche's early diagnostics portfolio by screening for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), an...

October 01, 2026 | Thursday | News
Egle Therapeutics Reports Phase 1 Data for Treg-Selective EGL-003 in Autoimmune Disease

EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts. EGL-003 produced selective, dose-dependent Treg expansion without am...

October 01, 2026 | Thursday | News
Terumo Neuro to Acquire Arsenal Medical to Expand Liquid Embolic Portfolio

Terumo Neuro announced that it has signed an agreement to acquire Arsenal Medical Inc., a privately held, clinical-stage biomaterials company developing Ne...

October 01, 2026 | Thursday | News
Verdiva Bio Presents VRB-103 Oral Amylin Data for Obesity Treatment

Verdiva Bio Limited (“Verdiva Bio” or “the Company”), a clinical-stage biotechnology company advancing the development of a portfol...

September 30, 2026 | Wednesday | News
Innovent Reports Phase 1 Data for IBI3003 Trispecific Antibody in Multiple Myeloma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercializat...

September 30, 2026 | Wednesday | News
Kither Biotech Doses First Patients in KIT2014 COPD Clinical Trial

KIT2014 is a novel inhaled peptide therapy being developed for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronch...

September 30, 2026 | Wednesday | News
Sun Nuclear Validates AdaptCHECK for Siemens Healthineers’ Accela Adaptive Radiotherapy System

Sun Nuclear, a Mirion Medical company, announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technica...

September 29, 2026 | Tuesday | News
Firefly Neuroscience Partners With NeuroSigma to Expand Access to Monarch eTNS for Pediatric ADHD

– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS® System to Firefly’s nationwide network of Evoke™ cl...

September 28, 2026 | Monday | News
ACROBiosystems Expands French Presence With New Hub at Kadans Science Partner’s The HIVE

Kadans Science Partner is pleased to welcome ACROBiosystems to The HIVE Innovation Center, its laboratory and office building dedicated to the life scien...

September 25, 2026 | Friday | News
Novartis Receives Positive CHMP Opinion for Cosentyx in Polymyalgia Rheumatica

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion r...

September 21, 2026 | Monday | News
Teva Reports Real-World Data Showing UZEDY Supports Treatment Continuity and Reduces Healthcare Utilization in Schizophrenia

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.  announced new real-world data evaluating treatment continuity, health...

September 21, 2026 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close